Abbott jumps on RFK Jr. health push — plus, reviews of Eli Lilly's obesity drug data

The S&P 500 rallied over 1% for a second consecutive day, led by technology and financials, as geopolitical tensions eased and oil prices declined. Concurrently, Eli Lilly's bimagrumab mid-stage trial data demonstrated compelling fat loss with muscle preservation; however, Wall Street analysts expressed reservations regarding tolerability and safety, prompting firms like Leerink and Jefferies to exclude potential sales from their financial models, suggesting a targeted commercial application with investor focus remaining on Lilly's orforglipron. Separately, HHS Secretary RFK Jr.'s vision for widespread wearable health device adoption boosted Abbott Laboratories and other continuous glucose monitor manufacturers.

Analysis

Broad market sentiment has turned positive, with the S&P 500 rising over 1% for a second consecutive day, led by technology and financial sectors amid easing geopolitical tensions and declining oil prices. The financial sector's advance comes ahead of the Federal Reserve's annual stress test results, a key regulatory event. In the biopharma space, Eli Lilly's mid-stage trial data for its experimental weight-loss drug, bimagrumab, received a mixed reception. While the drug demonstrated "compelling efficacy" in preserving muscle mass—patients on the highest dose lost approximately 93% fat mass versus 71.5% for those on semaglutide alone—analysts from Leerink, Jefferies, and Wolfe Research highlighted significant reservations about its tolerability and safety profile. Consequently, both Leerink and Jefferies are not currently incorporating bimagrumab sales into their financial models for Lilly, suggesting its commercial potential may be limited to niche populations like the elderly. Investor focus is now directed towards Lilly's oral obesity pill, orforglipron, with pivotal Q3 data expected. Separately, Abbott Laboratories received a positive catalyst after HHS Secretary RFK Jr. announced a vision to encourage widespread adoption of wearable health devices within four years, boosting the stock. This directly benefits Abbott, which is strongly positioned with its market-leading Free Style Libre CGM and its direct-to-consumer Lingo device.

Key Decisions for Investors

• For Eli Lilly, the mixed trial results for bimagrumab warrant a cautious stance; investors should temper expectations for this drug's contribution and instead monitor the upcoming Q3 trial data for the oral obesity pill orforglipron as the more significant near-term catalyst.
• The HHS Secretary's endorsement of wearable health devices presents a potential long-term tailwind for Abbott Laboratories, making its leadership position in the CGM market with both prescription and consumer products a key factor to consider for growth-oriented portfolios.
• Given the recent strength in financial stocks, investors should closely watch the Federal Reserve's stress test results on Friday, as favorable outcomes could provide further upward momentum for the banking sector.